Price
No data yet.
Social Signal Score
Revenue
$31.91M+486.98%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert I. Blum
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 673
- Beta
- 0.38
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -0.87
Financials
Revenue
$31.91M+487.0%Net Income
$-198.76MEBITDA
$-191.75MFree Cash Flow
$-164.17MEPS (diluted)
$-1.50Shares Outstanding (diluted)
132.09M+64.4%Operating Expenses
$202.20MCash & Debt
$1.17BReturn of Capital
$0.00Revenue by Segment (annual)
$8.69MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $88.04M | $-784.96M | $-6.54 |
| 2024 | $18.47M | $-589.53M | $-5.26 |
| 2023 | $7.53M | $-526.24M | $-5.45 |
| 2022 | $94.59M | $-388.95M | $-4.33 |
| 2021 | $70.43M | $-215.31M | $-2.80 |
| 2020 | $55.83M | $-127.29M | $-1.97 |
| 2019 | $26.87M | $-121.69M | $-2.59 |
| 2018 | $31.50M | $-106.29M | $-1.95 |
| 2017 | $13.37M | $-127.79M | $-2.59 |
| 2016 | $106.41M | $16.45M | $0.41 |
| 2015 | $28.66M | $-37.50M | $-0.97 |
| 2014 | $46.94M | $-14.65M | $-0.41 |
| 2013 | $30.65M | $-33.72M | $-1.24 |
| 2012 | $7.56M | $-41.68M | $-2.15 |
Valuation
CYTKhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·21h ago·Neutral
…s Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 14, 2026 it granted stock options to purchase an aggregate of 27,565 shares of common stock and 18,273 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 12 employees, whose employment commenced in July and August 2026 as a material inducement to their em…
View source ↗
Earnings
Wed, Nov 4(in 3 months)
Consensus estimate $-1.52 per share
Typical surprise +2.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-1.50 vs $-1.63beat
- Tue, May 5$-1.67 vs $-1.67beat
- Tue, Feb 24$-1.50 vs $-1.48miss
- Wed, Nov 5$-2.55 vs $-1.59miss
- Thu, Aug 7$-1.12 vs $-1.34beat
- Tue, May 6$-1.36 vs $-1.41beat
Estimates and results for CYTK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CYTK officers and directors.
- Bought
- —
- Sold
- $14.0m
0 trades
23 trades
- Malik Fady Ibrahamsold
- Blum Robert Isold
- Callos Andrewsold
- Blum Robert Isold
- Malik Fady Ibrahamsold
- Blum Robert Isold
- Malik Fady Ibrahamsold
- Blum Robert Isold
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.